Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07502924 · ClinicalTrials.gov registry record · NA
Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscle Health
A NA study, sponsored by Lindenwood University.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
NCT07502924: Recruiting NA study, sponsored by Lindenwood University.
NCT07502924 is a NA study that is actively recruiting participants, run by Lindenwood University. The registered enrollment target is 70 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07502924, a NA study, is actively recruiting participants, sponsored by Lindenwood University.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
Study Summary
This study will evaluate the effects of daily geranylgeraniol (GG) supplementation on muscular strength, body composition, and aerobic capacity in healthy, physically active men and women. Approximately 60 participants aged 30-60 years will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group trial lasting 8 weeks. Participants will be assigned to receive either placebo, 150 mg GG, or 300 mg GG daily. Outcome measures will be assessed at baseline, week 4, and week 8 and include maximal strength (1RM bench press and leg press), fat-free mass, muscular endurance, aerobic capacity (VO2peak), and circulating biomarkers related to metabolism and health.
Primary Outcome
Maximal lower-body strength will be assessed as leg press one-repetition maximum (1RM), defined as the greatest load that can be lifted for one complete repetition using proper technique.
Interventions
- DIETARY_SUPPLEMENT Dietary Supplement - Placebo
- DIETARY_SUPPLEMENT Geranylgeraniol (150 mg)
- DIETARY_SUPPLEMENT Geranylgeraniol (300 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2026-08-01 |
| Phase | NA |
What NCT07502924 shows while recruiting
NCT07502924 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which Dietary Supplement - Placebo is the first listed.
NCT07502924 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07502924 about?
NCT07502924 is a clinical study titled "Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscle Health". This study will evaluate the effects of daily geranylgeraniol (GG) supplementation on muscular strength, body composition, and aerobic capacity in healthy, physically active men and women. Approximately 60 participants aged 30-60 years will be enrolled in a randomized, double-blind, placebo-controll...
What is the current status of trial NCT07502924?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-03-03. Estimated completion is 2026-08-01.
What interventions are being tested in trial NCT07502924?
The interventions under investigation include: Dietary Supplement - Placebo (DIETARY_SUPPLEMENT), Geranylgeraniol (150 mg) (DIETARY_SUPPLEMENT), Geranylgeraniol (300 mg) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07502924?
This trial is sponsored by Lindenwood University, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07502924's enrollment target sits among peer trials
70 1103rd of 2000 higher than 868 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI